Cancer Institute A national cancer institute
designated cancer center

Neyssa Marina

Publication Details

  • A PHASE-I STUDY OF IFOSFAMIDE WITH MESNA GIVEN DAILY FOR 3 CONSECUTIVE DAYS TO CHILDREN WITH MALIGNANT SOLID TUMORS CANCER Pratt, C. B., Meyer, W. H., Douglass, E. C., Bowman, L., Wilimas, J., Ochs, J., Marina, N., Avery, L., Thompson, E. I. 1993; 71 (11): 3661-3665


    The authors conducted a Phase I dose escalation trial of ifosfamide given daily for 3 consecutive days to 29 children with malignant solid tumors. Twenty-eight of these children had received prior chemotherapy.Patients were assigned to dosage cohorts separately on the basis of prior exposure to the platinum alkylating agents cisplatin or carboplatin (n = 20) or the absence of such exposure (n = 9). At least three patients in each category were treated at a starting dosage of 2133 mg/m2/d for 3 days. This dosage represented 80% of the total dose delivered in the prior study of ifosfamide given daily over 5 days with dosage escalation of 20% in subsequent cohorts.Myelosuppression was dose-limiting at the second dosage level (2560 mg/m2/d) for patients previously treated with platinum and at the third dosage level (3072 mg/m2/d) for those not previously treated with platinum. Dose-limiting neurotoxicity was seen at 2560 mg/m2/d for the former group, but was not encountered in the latter group.Delivery of ifosfamide daily for 3 days is feasible and safe at recommended dosages of 2133 mg/m2/d for children with prior exposure to platinum and 3000 mg/m2/d for those without prior exposure.

    View details for Web of Science ID A1993LE41900030

    View details for PubMedID 8490914

Stanford Medicine Resources:

Footer Links: